Kimberly Ehman, Ph.D., has joined Eurofins Medical Device Services’ North America Medical Device Program as head of Regulatory Toxicology to lead biocompatibility consulting and toxicological risk assessment (TRA) services. In her new position, Dr. Ehman will serve as a bridge between Eurofins medical device service solutions and clients, partnering to navigate testing strategies to ensure product safety.

Dr. Ehman has more than 20 years of toxicology and medical device experience, with expertise in toxicological risk assessments (TRAs) for medical devices, food and beverage products, and electronic nicotine delivery systems. She most recently worked as director of Regulatory Toxicology and Consulting at WuXi AppTec, where she managed a team of toxicologists that supported TRAs and biocompatibility test strategies for medical devices and combination products as well as container closures and single-use systems. Dr. Ehman also worked for Altria Client Services (head of Regulatory Toxicology), Toxicology Regulatory Services (consulting toxicologist and program manager), and RTI International (research toxicologist for Developmental and Reproductive Toxicology and Neurotoxicology).

Dr. Ehman earned her PhD in parasitology from McGill University in Montréal, Canada, and conducted her postdoctoral research at the U.S. Environmental Protection Agency, with a focus on developmental neurotoxicology. She has been a Diplomate of the American Board of Toxicology since 2009 and an active member of the Society of Toxicology (SOT) since 2005, and the American College of Toxicology (ACT) since 2010. Dr. Ehman is currently the vice president-elect for the Medical Device and Combination Product Specialty Section (MDCPSS) of SOT and serves as an expert on several U.S. working groups for the ISO 10993 series of standards, including ISO 10993-1 (Evaluation and testing within a risk management process), ISO 10993-3 (Tests for genotoxicity, carcinogenicity and reproductive toxicity), and ISO 10993-17 (Toxicological risk assessment of medical device constituents).

Eurofins is a global provider of food, environment, pharmaceutical, and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences, and agroscience contract research services. The company also offers certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. The Group has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing and in-vitro diagnostic products. With more than 61,000 staff across a decentralized and entrepreneurial network of 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.